-
1.发明授权NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS 有权NEER VERBINDUNGEN ALS DIACYLGLYCEROL-ACYLTRANSFERASE-HEMMER
公开(公告)号：EP2723332B1
公开(公告)日：2016-03-02
申请号：EP12789372.5
申请日：2012-05-18
发明人： QIN, Donghui , JOSHI, Hemant , TANGIRALA, Raghuram
IPC分类号： A61K31/17 , C07D213/75 , C07C275/42 , C07D217/24 , C07D237/20 , C07D239/42 , C07D241/20 , A61P3/00 , A61P31/00 , A61P17/00
CPC分类号： C07C275/42 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D213/75 , C07D217/24 , C07D217/26 , C07D237/20 , C07D239/42 , C07D241/20
-
公开(公告)号：EP2723332A1
公开(公告)日：2014-04-30
申请号：EP12789372.5
申请日：2012-05-18
发明人： QIN, Donghui , JOSHI, Hemant , TANGIRALA, Raghuram
IPC分类号： A61K31/17
CPC分类号： C07C275/42 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07D213/75 , C07D217/24 , C07D217/26 , C07D237/20 , C07D239/42 , C07D241/20
摘要： This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT- 1 dysfunction or where modulation of DGAT- 1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
-
公开(公告)号：EP2710013B1
公开(公告)日：2016-06-29
申请号：EP12789931.8
申请日：2012-05-18
IPC分类号： C07D498/04 , A61K31/553 , A61P3/00
CPC分类号： C07D519/00 , C07D498/04
-
公开(公告)号：EP2710013A1
公开(公告)日：2014-03-26
申请号：EP12789931.8
申请日：2012-05-18
IPC分类号： C07D498/04
CPC分类号： C07D519/00 , C07D498/04
摘要： This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
-
-
-
搜索结果
4 条记录 (耗时 0.018 秒)
